{"name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","slug":"cubist-pharmaceuticals-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"oncology","drugs":[{"name":"ADL5859","genericName":"ADL5859","slug":"adl5859","indication":"Complicated urinary tract infections","status":"phase_2"},{"name":"CB-183,315","genericName":"CB-183,315","slug":"cb-183-315","indication":"Gram-positive bacterial infections (phase 3 development)","status":"phase_3"},{"name":"CXA-101","genericName":"CXA-101","slug":"cxa-101","indication":"Complicated urinary tract infections","status":"phase_2"},{"name":"CXA-201","genericName":"CXA-201","slug":"cxa-201","indication":"Complicated urinary tract infections (cUTI)","status":"phase_3"},{"name":"CXA-201 and metronidazole","genericName":"CXA-201 and metronidazole","slug":"cxa-201-and-metronidazole","indication":"Clostridioides difficile infection (CDI)","status":"phase_3"},{"name":"Nafcillin (or equivalent)","genericName":"Nafcillin (or equivalent)","slug":"nafcillin-or-equivalent","indication":"Serious infections caused by susceptible Staphylococcus aureus (including methicillin-susceptible strains)","status":"phase_3"},{"name":"Semi-Synthetic Penicillin","genericName":"Semi-Synthetic Penicillin","slug":"semi-synthetic-penicillin","indication":"Bacterial infections susceptible to semi-synthetic penicillins (specific agents vary: e.g., ampicillin for gram-positive and some gram-negative infections; amoxicillin for respiratory and urinary tract infections)","status":"marketed"},{"name":"Tedizolid Phophate","genericName":"Tedizolid Phophate","slug":"tedizolid-phophate","indication":"Acute bacterial skin and skin structure infections (ABSSSI)","status":"phase_3"},{"name":"Vancomycin (or equivalent)","genericName":"Vancomycin (or equivalent)","slug":"vancomycin-or-equivalent","indication":"Treatment of acute bacterial skin and skin structure infections (ABSSSI)","status":"phase_3"},{"name":"daptomycin (up to 14 days)","genericName":"daptomycin (up to 14 days)","slug":"daptomycin-up-to-14-days","indication":"Complicated skin and soft tissue infections caused by susceptible Gram-positive bacteria","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Alviompan","genericName":"Alviompan","slug":"alviompan","indication":"Other","status":"phase_3"},{"name":"daptomycin and gentamicin","genericName":"daptomycin and gentamicin","slug":"daptomycin-and-gentamicin","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"ADL5859","genericName":"ADL5859","slug":"adl5859","phase":"phase_2","mechanism":"ADL5859 is a small molecule antibiotic that targets the bacterial cell wall synthesis.","indications":["Complicated urinary tract infections","Complicated intra-abdominal infections"],"catalyst":""},{"name":"CB-183,315","genericName":"CB-183,315","slug":"cb-183-315","phase":"phase_3","mechanism":"CB-183,315 is a selective inhibitor of bacterial protein synthesis that targets gram-positive pathogens by binding to the bacterial ribosome.","indications":["Gram-positive bacterial infections (phase 3 development)"],"catalyst":""},{"name":"CXA-101","genericName":"CXA-101","slug":"cxa-101","phase":"phase_2","mechanism":"CXA-101 is a siderophore antibiotic that targets bacterial iron acquisition.","indications":["Complicated urinary tract infections","Complicated intra-abdominal infections"],"catalyst":""},{"name":"Alviompan","genericName":"Alviompan","slug":"alviompan","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CXA-201","genericName":"CXA-201","slug":"cxa-201","phase":"phase_3","mechanism":"CXA-201 is a novel antibiotic that inhibits bacterial protein synthesis by targeting the ribosome.","indications":["Complicated urinary tract infections (cUTI)","Acute bacterial cystitis","Gram-negative bacterial infections"],"catalyst":""},{"name":"CXA-201 and metronidazole","genericName":"CXA-201 and metronidazole","slug":"cxa-201-and-metronidazole","phase":"phase_3","mechanism":"CXA-201 is a non-absorbed topical antibiotic that works synergistically with metronidazole to treat bacterial infections, particularly in the gastrointestinal tract or as a topical agent.","indications":["Clostridioides difficile infection (CDI)","Polymicrobial intra-abdominal infections"],"catalyst":""},{"name":"Nafcillin (or equivalent)","genericName":"Nafcillin (or equivalent)","slug":"nafcillin-or-equivalent","phase":"phase_3","mechanism":"Nafcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","indications":["Serious infections caused by susceptible Staphylococcus aureus (including methicillin-susceptible strains)","Bacterial endocarditis","Osteomyelitis","Pneumonia"],"catalyst":""},{"name":"Semi-Synthetic Penicillin","genericName":"Semi-Synthetic Penicillin","slug":"semi-synthetic-penicillin","phase":"marketed","mechanism":"Semi-synthetic penicillins inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking.","indications":["Bacterial infections susceptible to semi-synthetic penicillins (specific agents vary: e.g., ampicillin for gram-positive and some gram-negative infections; amoxicillin for respiratory and urinary tract infections)"],"catalyst":""},{"name":"Tedizolid Phophate","genericName":"Tedizolid Phophate","slug":"tedizolid-phophate","phase":"phase_3","mechanism":"Tedizolid phosphate is an oxazolidinone antibiotic that inhibits protein synthesis in bacteria by binding to the 50S ribosomal subunit.","indications":["Acute bacterial skin and skin structure infections (ABSSSI)"],"catalyst":""},{"name":"Vancomycin (or equivalent)","genericName":"Vancomycin (or equivalent)","slug":"vancomycin-or-equivalent","phase":"phase_3","mechanism":"Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.","indications":["Treatment of acute bacterial skin and skin structure infections (ABSSSI)","Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)","Treatment of severe or life-threatening infections caused by susceptible Gram-positive bacteria"],"catalyst":""},{"name":"daptomycin (up to 14 days)","genericName":"daptomycin (up to 14 days)","slug":"daptomycin-up-to-14-days","phase":"marketed","mechanism":"Daptomycin binds to bacterial cell membranes and causes rapid depolarization, leading to loss of essential ions and bacterial cell death.","indications":["Complicated skin and soft tissue infections caused by susceptible Gram-positive bacteria","Staphylococcus aureus bacteremia, including right-sided endocarditis"],"catalyst":""},{"name":"daptomycin and gentamicin","genericName":"daptomycin and gentamicin","slug":"daptomycin-and-gentamicin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiOkFVX3lxTE9xUnktMklHVURZci1jbkxlOUlJWXAwd0JFLXItcENtRDJlM3dINVJVZkV0S3BmeFVwcGc?oc=5","date":"2006-03-15","type":"pipeline","source":"Merck.com","summary":"Merck | Home - Merck.com","headline":"Merck | Home","sentiment":"neutral"}],"patents":[],"drugCount":12,"phaseCounts":{"phase_2":2,"phase_3":7,"marketed":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}